Dex-CSDH study outcomes published in the New England Journal of Medicine
Outcomes of a trial of Dexamethasone for Chronic Subdural Hematoma has been published in the New England Journal of Medicine, on behalf of the British Neurosurgical Trainee Research Collaborative and Dex-CSDH Trial Collaborators.
Professor of Neurosurgery, University of Cambridge
Dex-CSDH is a pragmatic, multi-centre, double-blind, phase III randomised, placebo-controlled trial assessing the clinical utility of a tapering 2-week course of dexamethasone following Chronic Subdural Haematoma. The patients were assigned in a 1:1 ratio to receive a 2-week tapering course of oral dexamethasone, starting at 8 mg twice daily, or placebo. The decision to surgically evacuate the hematoma was made by the treating clinician. The primary outcome was a score of 0 to 3, representing a favorable outcome, on the modified Rankin scale at 6 months after randomization; scores range from 0 (no symptoms) to 6 (death).
The results of the trial suggest that among adults with symptomatic chronic subdural hematoma, most of whom had undergone surgery to remove their hematomas during the index admission, treatment with dexamethasone resulted in fewer favorable outcomes and more adverse events than placebo at 6 months, but fewer repeat operations were performed in the dexamethasone group. Dexamethasone was associated with more adverse events than placebo.
For more information visit: N Engl J Med
Published December 31 2020
Latest from CCTU
National Patient Led Research Hub celebrates tenth anniversary
A national team based in Cambridge are celebrating ten years of helping people living with rare diseases to develop their own research ideas. The hub has…
Hope for MS patients as Cambridge trial suggests drug combination may repair nerve damage
Early findings from a clinical trial in Cambridge suggest a combination of metformin, a diabetes drug, and clemastine, an antihistamine, can help repair…
Prospective study into controversial brain cyst syndrome is world first
The world’s first study of its kind highlights the potential value of surgery to treat a specific kind of brain cyst that blights the lives of patients.
